non-small-cell lung cancer (NSCLC) patients after failure of gefitinib treatment' [1] .
We agree with the authors' conclusion that erlotinib can be an option for highly selected non-small-cell lung cancer (NSCLC) patients after failure of gefitinib although it should not be routinely used for all patients.
However, the authors did not consider in their discussion all the reports on this topic. In fact, we have found a total of 138 cases of NSCLC patients treated with erlotinib after failure of gefitinib reported in published prospective or retrospective trials or presented at international meetings [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Forty-four patients (31.9%) obtained a disease control [considered as the sum of cases with partial response (PR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum and no appearance of new lesions) or stable disease (SD: less than a 30% decrease and less than a 20% increase in the sum of the longest diameter of target lesions, taking as reference the baseline sum and the appearance of no new lesions)] with erlotinib after failure of gefitinib (Table 1) .
Moreover, among the 104 patients who have obtained a disease control with gefitinib, 42 (40.4%) experienced a disease control (PR or SD) also from erlotinib treatment.
Preclinical models indicated that the two most common mechanisms of acquired resistance to gefitinib, the EGFR-T790M mutation and the MET amplification, confer resistance also to erlotinib [13, 14] ; however, the secondary resistant T790M mutation arises mostly in EGFR-mutated NSCLC (only a subgroup of all patients) and other mechanisms for secondary resistance have not been completely clarified.
Many clinical trials with various second-generation EGFR inhibitors have been started in this setting; in the meanwhile, the identification of molecular mechanisms of secondary resistance remains a key point to optimize the use of erlotinib and gefitinib and to better develop new targeted agents. 
